Celine Halioua On The Science and Business of Making Dogs Live Longer

Art student has existential crisis, pivots to aging biology overnight

Celine Halioua shares her unconventional path from art school to founding a longevity company. She describes having a sudden realization that biology determines free will, leading her to switch to neuroscience and eventually become obsessed with developing the first aging drug. This clip reveals the pivotal moment that set her on the path to entrepreneurship.

Why early fundraising rounds get easier when complex ideas become obvious

Celine Halioua explains the counterintuitive U-shaped curve of fundraising difficulty, where early rounds become relatively easier once you've spent years making a complex idea so clear it seems obvious. She describes how seed and Series A rounds were manageable compared to later stages, emphasizing that 'easy' still required tremendous thought and effort upfront.

How biotech creates billion dollar moats through regulatory hurdles

Celine Halioua explains how biotech companies build defensible moats through difficult regulatory and technical barriers, then structure fundraising around milestones that increase the probability of reaching approval and unlocking massive market value. She breaks down the strategic thinking behind milestone-based fundraising in regulated industries.

Why biotech founders need multiple shots on goal unlike software startups

Celine Halioua explains why her longevity biotech company takes a fundamentally different approach than software startups by developing multiple drug candidates simultaneously. She argues that since founders can't force a drug to work, having multiple shots on the same core thesis is essential for biotech success.

Why human longevity drugs face an impossible patent catch-22

Celine Halioua explains the complex regulatory and business challenges facing human longevity drug development. She discusses the difficulty of designing clinical trials when it's unclear whether to measure direct mortality reduction or leading indicators, and highlights how patent issues create a fundamental catch-22 for developing longevity treatments.

unhealthy aging, and aging writ large that will hopefully push out over time. I think the issue with human is that so much of aging is environmental and behavioral, and no drug's gonna change that....